This article is more than 5 years old. Information may no longer be current.

NICE initially recommends Jetrea for vitreomacular traction

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Jetrea has received a provisional recommendation from the National Institute for Health and Care Excellence in the United Kingdom as an option for treating vitreomacular traction in adults, according to a news release.

The next step involves formal consultation and comments as well as public input before NICE rules on whether Jetrea (ocriplasmin, ThromboGenics) can be approved for reimbursement within the National Health Service.

The final appraisal determination is expected in the third quarter, according to the release.

Alcon, ThromboGenics’ marketing partner, launched Jetrea in the U.K. in April. The treatment gained approval in the European Union from the European Commission in March.